Suzhou Aotuo Biopharmaceutical

Suzhou Aotuo Biopharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of innovative antibody-drug conjugates (ADCs) for oncology. The company utilizes a proprietary site-specific conjugation technology platform designed to produce ADCs with superior homogeneity, stability, and therapeutic efficacy compared to traditional random conjugation methods. Its lead candidate, AT-001, is a Claudin 18.2-directed ADC currently in Phase 1 clinical trials for patients with advanced solid tumors, particularly gastric and pancreatic cancers. Beyond its lead asset, Aotuo is advancing a robust pipeline of ADC programs targeting well-validated antigens such as HER2, TROP2, and Nectin-4. By integrating advanced antibody engineering with novel linker-payload chemistry, the company seeks to provide more effective treatment options for cancer patients worldwide.